Roche said AI contributed to 40% of its drug pipeline decisions.
The Swiss drugmaker told investors in Zurich on Monday that AI or computer models had a tracked part in 40% of its pipeline decisions between late 2025 and mid-2026, Reuters reported.
These are the choices about which drug projects move forward.
Its internal tool, Target Nexus, is meant to contribute to 80% of research-portfolio decisions by the end of 2026.
Roche has started building autonomous labs. AI proposes an experiment for the lab to run. The results then train the AI again. The company set out six levels of autonomy for that work.
It plans to reallocate about CHF 2 billion ($2.41 billion) of research savings by 2026. Separately, it targets up to 20 new molecular entities, potential new medicines, by 2030. Company figures show its Phase III, or late-stage, trial success rate is above 80% this year, against 65% in 2025.
Most companies do not measure how many of their big decisions involved AI. Roche now reports that share to investors.
Could your company say what share of last quarter's big decisions involved AI?
Sources
Every story here is open to read. The ERP LEADERS brief goes one step further.
The week in enterprise software, in one email: the stories that mattered, the failures with their figures, one case taken apart. Read a sample or sign up for the brief.
Welcome back. · Issue 01
